CheckMate 141 trial: all that glitters is not gold

Expert Opin Biol Ther. 2019 Mar;19(3):169-171. doi: 10.1080/14712598.2019.1570498. Epub 2019 Jan 21.

Authors

Raffaele Addeo¹, Massimo Ghiani², Francesco Merlino³, Filippo Ricciardiello⁴, Michele Caraglia⁵

Affiliations

¹ a Oncology Unit , "S. Giovanni di Dio" Hospital , Naples , Italy.
² b Oncology Unit , "Businco" Hospital , Cagliari , Italy.
³ c Department of Pharmacy , University of Naples Federico II , Naples , Italy.
⁴ d U.O.C. ORL, AORN "Cardarelli" , Napoli , Italy.
⁵ e Department of Precision Medicine , University of Campania "L. Vanvitelli" , Naples and Biogem , Avellino Italy.

PMID: 30652499
DOI: 10.1080/14712598.2019.1570498

No abstract available

Keywords: Head and neck cancer; cetuximab; immunological check point inhibitors; nivolumab; pembrolizumab.

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Squamous Cell*
Head and Neck Neoplasms*
Humans
Neoplasm Recurrence, Local
Nivolumab

Substances

Nivolumab